| Univariate cOR (95% CI) | p | Multivariable aOR (95% CI) | p |
---|---|---|---|---|
Droperidol vs. control | 0.50 (0.36–0.69) | 0.0046 | 0.49 (0.35–0.67) | < 0.0001 |
Age, year | 0.995 (0.985–1.005) | 0.3339 | . | . |
Sex, male | 0.49 (0.29–0.82) | 0.0064 | 0.51 (0.30–0.85) | 0.0101 |
Body mass index, kg/m 2 | 0.99 (0.95–1.02) | 0.4442 | . | . |
ASA class | Â | 0.6891 | . | . |
 II vs. I | 0.84 (0.56–1.26) | 0.8651 | . | . |
 III vs. I | 0.85 (0.10–7.47) | 0.9436 | . | . |
Current smoker | 0.88 (0.51–1.54) | 0.6573 | . | . |
Previous PONV | 2.95 (1.62–5.37) | 0.0004 | 2.74 (1.48–5.05) | 0.0013 |
Hypertension | 0.68 (0.46–1.00) | 0.0488 | . | . |
Diabetes mellitus | 0.95 (0.61–1.50) | 0.8313 | . | . |
Major depression | 0.65 (0.15–2.87) | 0.5704 | . | . |
Malignancy | 0.79 (0.49–1.27) | 0.3326 | . | . |
Preoperative blood test †|  |  | . | . |
 Hemoglobin, g/dL | 0.84 (0.43–1.64) | 0.6098 | . | . |
 eGFR, mL/min/1.73 m2 | 1.48 (1.00–2.19) | 0.0502 | . | . |
 Alanine aminotransferase, U/L | 0.89 (0.70–1.12) | 0.3126 | . | . |
 Aspartate aminotransferase, U/L | 1.02 (0.77–1.35) | 0.8753 | . | . |
Surgical site, extremity as reference | Â | 0.0597 | . | . |
 Head and neck | 0.26 (0.03–2.03) | 0.2675 | . | . |
 Breast | 0.44 (0.10–1.96) | 0.4636 | . | . |
 Upper abdomen | 0.58 (0.28–1.19) | 0.5329 | . | . |
 Lower abdomen | 0.90 (0.61–1.35) | 0.3069 | . | . |
 Thorax | 2.09 (0.68–6.45) | 0.0393 | . | . |
 Spine | 0.31 (0.12–0.82) | 0.0624 | . | . |
 Other | 1.86 (0.54–6.33) | 0.0905 | . | . |
Laparoscopic or robotic surgery | 0.83 (0.52–1.34) | 0.4528 | . | . |
Intraoperative blood loss, mL †| 1.03 (0.96–1.10) | 0.3935 | . | . |
Type of anesthesia | Â | 0.4611 | . | . |
 General vs. neuraxial anesthesia | 0.84 (0.61–1.18) | 0.3666 | . | . |
 Combined vs. neuraxial anesthesia | 2.20 (0.20–24.59) | 0.4775 | . | . |
Use of volatile anesthetics | 0.85 (0.61–1.18) | 0.3282 | . | . |
Anesthesia duration, min †| 0.88 (0.71–1.08) | 0.2128 | . | . |
Intraoperative fluid volume, mL †| 0.94 (0.77–1.16) | 0.5844 | . | . |
Intraoperative use of dexamethasone | 0.85 (0.62–1.17) | 0.3249 | . | . |
Intraoperative use of midazolam | 1.19 (0.80–1.78) | 0.3962 | . | . |
Intraoperative use of NSAIDs | 1.30 (0.86–1.97) | 0.2164 |  |  |
Intraoperative opioid consumption, MME †| 0.87 (0.71–1.06) | 0.1705 | . | . |
Neuromuscular blockade reversal | Â | 0.5673 | . | . |
 Neostigmine vs. nil | 0.81 (0.53–1.24) | 0.4762 | . | . |
 Sugammadex vs. nil | 0.86 (0.60–1.23) | 0.7952 | . | . |
IV-PCA duration, hour †| 1.13 (0.79–1.60) | 0.5016 | . | . |
Postoperative use of NSAIDs | 0.46 (0.16–1.29) | 0.1374 |  |  |
Postoperative opioid consumption, MME †| 0.89 (0.79–1.00) | 0.0547 | . | . |